4.1 Review

World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/13651501.2014.961931

Keywords

Dementia; guidelines; Alzheimer's disease; Lewy body disease; anti-dementia drugs; neuropsychiatric symptoms

Categories

Funding

  1. Lundbeck
  2. AstraZeneca
  3. Teva
  4. GlaxoSmithKline
  5. Eli Lilly
  6. Pfizer
  7. Roche
  8. Bristol-Myers Squibb
  9. CSC
  10. Janssen Pharmaceutica
  11. MSD
  12. Novartis
  13. Organon
  14. Pierre Fabre
  15. Schwabe
  16. Sepracor
  17. Servier
  18. Wyeth
  19. Janssen Cilag
  20. Otsuka
  21. NIH [P50 AG05142, R01 AG033288, R01 AG037561]
  22. State of California
  23. Alzheimer's Association
  24. Baxter
  25. Genentech
  26. Johnson Johnson
  27. Abbvie Laboratories
  28. AC Immune
  29. Allon
  30. Biogen Idec
  31. Biotie
  32. Ela
  33. EnVivo
  34. Merck
  35. Piramal
  36. Sanofi
  37. Takeda
  38. Tau Rx
  39. Toyama
  40. Zinfandel
  41. Dainippon Sumitomo Pharma Co Ltd
  42. National Institute for Health Research [NF-SI-0512-10033] Funding Source: researchfish

Ask authors/readers for more resources

Objective. To define a practice guideline for biological treatment of dementias for general practitioners in primary care. Methods. TThis paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the Biological treatment of Alzheimer's disease and other dementias for treatment in primary care (Ihl et al. 2011). The recommendations were developed by a task force of international experts in the field and are based on randomized controlled studies. Results. Anti-dementia medications neither cure, nor arrest, or alter the course of the disease. The type of dementia, the individual symptom constellation and the tolerability and evidence for efficacy should determine what medications should be used. In treating neuropsychiatric symptoms, psychosocial intervention should be the treatment of first choice. For neuropsychiatric symptoms, medications should only be considered when psychosocial interventions are not adequate and aft er cautious risk-benefit analysis. Conclusions. Depending on the diagnostic entity and clinical presentation different anti-dementia drugs can be recommended. These guidelines provide a practical approach for general practitioners managing dementias.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychiatry

Cariprazine for treating psychosis: an updated meta-analysis

Marcelo B. Generoso, Ivan Taiar, Quirino Cordeiro, Pedro Shiozawa, Siegfried Kasper

Summary: Early treatment of psychotic illness is important for better outcomes, and cariprazine, a promising antipsychotic drug, may be beneficial in treating psychosis regardless of the diagnosis of schizophrenia or bipolar disorder.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Article Clinical Neurology

Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study

Daniele Altomare, Lyduine Collij, Camilla Caprioglio, Philip Scheltens, Bart N. M. van Berckel, Isadora Lopes Alves, Johannes Berkhof, Yvonne de Gier, Valentina Garibotto, Christian Moro, Lea Poitrine, Julien Delrieu, Pierre Payoux, Laure Saint-Aubert, Jose Luis Molinuevo, Oriol Grau-Rivera, Juan-Domingo Gispert, Carolina Minguillon, Karine Fauria, Marta Felez Sanchez, Andreea Radoi, Alexander Drzezga, Frank Jessen, Claus Escher, Philip Zeyen, Agneta Nordberg, Irina Savitcheva, Vesna Jelic, Zuzana Walker, Ho-Yun Lee, Lean Lee, Jean-Francois Demonet, Sonia Plaza Wuthrich, Rossella Gismondi, Gill Farrar, Frederik Barkhof, Andrew W. Stephens, Giovanni B. Frisoni

Summary: The AMYPAD Diagnostic and Patient Management Study aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Participants with subjective cognitive decline, mild cognitive impairment, or dementia were recruited in eight European memory clinics and randomized into three study arms. The baseline features of the participants were representative of a memory clinic population, ensuring the generalizability of the study results.

ALZHEIMERS & DEMENTIA (2023)

Review Geriatrics & Gerontology

Mild cognitive impairment in geriatric practice: patient orientation, diagnostics, treatment and ethics

Lutz Froelich, Christine von Arnim, Jens Bohlken, Johannes Pantel, Oliver Peters, Hans Foerstl

Summary: This article aims to provide practical recommendations to help physicians identify cognitive deficits in geriatric patients at an early stage and provide high-quality care focusing on counseling, treatment, and comorbidity management.

ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE (2023)

Article Clinical Neurology

Herpes simplex virus alters Alzheimer's disease biomarkers - A hypothesis paper

Oliver Goldhardt, Robert Freiberger, Tobias Dreyer, Luisa Willner, Igor Yakushev, Marion Ortner, Hans Foerstl, Janine Diehl-Schmid, Esther Milz, Josef Priller, Alfredo Ramirez, Viktor Magdolen, Markus Thaler, Timo Grimmer

Summary: This study investigated the association between HSV infection and AD biomarkers. The results suggest that in HSV1-seropositive AD patients, there is a significant predictive effect of AI-IgG(HSV1/2) and Aβ(42)/Aβ(40) ratio on pTau.

ALZHEIMERS & DEMENTIA (2023)

Biographical-Item Clinical Neurology

Obituary for Prof. Dr. Hans Lauter (1928-2022)

Hans Foerstl

NERVENARZT (2023)

Article Neurosciences

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression

Maria Galuszko-Wegielnik, Zuzanna Chmielewska, Katarzyna Jakuszkowiak-Wojten, Mariusz S. Wiglusz, Wieslaw J. Cubala

Summary: Psychotic treatment-resistant depression is a challenging manifestation of mood disorders in clinical settings, often underdiagnosed and undertreated. This study aimed to assess the usage of ketamine as an add-on treatment for major depressive disorder with psychotic features, and the results suggest its potential benefits for individuals with treatment-resistant depression.

BRAIN SCIENCES (2023)

Article Chemistry, Medicinal

Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms

Adam Wlodarczyk, Alicja Dywel, Wieslaw Jerzy Cubala

Summary: This study investigates the safety of intravenous ketamine treatment for treatment-resistant depression and finds a significant association between epilepsy and elevated BPRS scores.

PHARMACEUTICALS (2023)

Article Psychiatry

Richard Semon (1859-1918): expeditions, engrams and epigenetics

Hans Foerstl

Summary: Richard Semon, a biologist, studied various animals such as sea urchins, starfish, chicken, and lung fish. He developed the theory of "mneme" and expanded it to the inheritance of acquired characteristics. After being forced to leave Germany, he continued his philosophical research in biology in Munich. In 1918, he tragically took his own life due to various reasons.

NEUROPSYCHIATRIE (2023)

Review Biochemistry & Molecular Biology

Molecular Mechanisms of Neurogenic Inflammation of the Skin

Luiza Marek-Jozefowicz, Boguslaw Nedoszytko, Malgorzata Grochocka, Michal A. Zmijewski, Rafal Czajkowski, Wieslaw J. Cubala, Andrzej T. Slominski

Summary: Neurogenic inflammation is the result of nerve endings and mediators' activity in the skin, leading to inflammatory reactions. TRPV-ion channels' activation increases the release of inflammatory mediators and contributes to the maintenance of cutaneous neurogenic inflammation. Understanding the molecular mechanisms of neuropeptide and neurotransmitter receptors in cutaneous cells can aid in developing effective treatments for inflammatory skin disorders.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Psychiatry

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting

Lluis Niell Galmes, Elmars Rancans

Summary: Real-world evidence provides valuable data on the effectiveness and tolerability of cariprazine in patients with schizophrenia or schizoaffective disorder. This study conducted in a Spanish hospital collected data on the demographic characteristics, disorder history, and treatment details of 14 patients. The results showed significant improvement in symptoms and a high tolerability of cariprazine even at high doses.

FRONTIERS IN PSYCHIATRY (2023)

Article Psychiatry

Self-reported suicidal behaviours and associated factors in the general population of Latvia (2010-2018)

Krista Mieze, Anda Kivite-Urtane, Daiga Grinberga, Biruta Velika, Iveta Pudule, Elmars Rancans

Summary: This study aimed to assess the prevalence of different types of self-reported suicidal behaviors in Latvia and determine the associated sociodemographic and health-related factors. The findings showed that 15.6% of the respondents reported some type of suicidal behavior, and factors such as age, education, nationality, and mental state were associated with different types of suicidal behavior.

INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY (2023)

Letter Dermatology

Purtscher-like retinopathy after hyaluronic filler injection for facial augmentation

E. Serkies-Minuth, P. Glasner, K. Michalska-Malecka, W. Baranska-Rybak

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Clinical Neurology

Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study

Milena Shrashimirova, Ivan Tyanev, Wieslaw J. Cubala, Adam Wichniak, Claudia Vodickova-Borzova, Alessandro Ruggieri, Annalisa Bonelli, Paola Lipone, Alessandro Comandini, Agnese Cattaneo

Summary: This study aims to describe the clinical response, functional impairment, and quality of life (QoL) of patients with major depressive disorder (MDD) treated with Trazodone Once-A-Day (TzOAD) monotherapy over a 24-week period. The results demonstrate the safety, tolerability, and effectiveness of TzOAD in improving depressive symptoms, QoL, sleep quality, and overall functioning.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2023)

No Data Available